Supplementary Table 1: STrengthening the REporting of Genetic Association studies (STREGA) reporting recommendations, extended from STROBE Statement

Item	Item no	STROBE Guideline	Extension for Genetic Association Studies (STREGA)	Section, paragraph
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract.(b) Provide in the abstract an informative and balanced summary of what was done and what was found.		Abstract: Methods and Findings Abstract: Methods and Findings
Introduction				
Background rationale	2	Explain the scientific background and rationale for the investigation being reported.		Introduction: Paragraphs 1- 5
Objectives	3	State specific objectives, including any pre- specified hypotheses	State if the study is the first report of a genetic association, a replication effort, or both.	Introduction: Paragraph 6
Methods				
Study design	4	Present key elements of study design early in the paper.		Introduction: Paragraph 6
Setting	5	Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up and data collection.		Methods: Study cohorts
Participants	6	 (a) Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. Case-control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants. (b) Cohort study – For matched studies, give matching criteria and number of exposed and unexposed. 	Give information on the criteria and methods for selection of subsets of participants from a larger study, when relevant.	Methods: Study cohorts, Genotyping and association analysis, Meta- analysis
		Case-control study - For matched studies, give matching criteria and the number of controls per case.		

Variables	7	(a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	(b) Clearly define genetic exposures (genetic variants) using a widely – used nomenclature system. Identify variables likely to be associated with population stratification (confounding by ethnic origin).	Methods: Study cohorts, Genotyping and association analysis, Meta- analysis, Adjusting the GWAS for BMI, Search for variants previously associated with testosterone and SHBG levels
Data sources measurement	8*	(a) For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.	(b) Describe laboratory methods, including source and storage of DNA, genotyping methods and platforms (including the allele calling algorithm used, and its version), error rates and call rates. State the laboratory /centre where genotyping was done. Describe comparability of laboratory methods if there is more than one group. Specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches.	Methods: Study cohorts, Genotyping and association analysis, Meta- analysis
Bias	9	(a) Describe any efforts to address potential sources of bias.	(b) For quantitative outcome variables, specify if any investigation of potential bias resulting from pharmacotherapy was undertaken. If relevant, describe the nature and magnitude of the potential bias, and explain what approach was used to deal with this.	NA
Study size	10	Explain how the study size was arrived at.		Methods: Study cohorts, Genotyping and association analysis, Meta- analysis, Adjusting the GWAS for BMI, Search for variants previously associated with testosterone and SHBG levels

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.	If applicable, describe how effects of treatment were dealt with.	Methods: Genotyping and association analysis, Meta- analysis, Adjusting the GWAS for BMI, Search for variants previously associated with testosterone and SHBG levels
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding. (b) Describe any methods used to examine	State software version used and options (or settings) chosen.	Methods: Genotyping and association analysis, Meta- analysis, Functional annotation and gene prioritization, Colocalization analyses, Interaction analysis NA
		subgroups and interactions.		INA
		(c) Explain how missing data were addressed.		Methods: Genotyping and association analysis
		(d) Cohort study – If applicable, explain how loss to follow-up was addressed.		Methods: Study cohorts, Genotyping and
		Case–control study – If applicable, explain how matching of cases and controls was addressed.		association analysis, Meta- analysis
		Cross-sectional study – If applicable, describe analytical methods taking account of sampling strategy.		
		(e) Describe any sensitivity analyses.	(f) State whether Hardy-	Methods:
			Weinberg equilibrium was considered and, if so, how.	Genotyping and association analysis
			(g) Describe any methods used for inferring genotypes or haplotypes.	Methods: Genotyping and association analysis
			(h) Describe any methods used to assess or address population stratification.	Methods: Genotyping and association analysis

			(i) Describe any methods used to address multiple comparisons or to control risk of false positive findings.	Methods: Meta- analysis, Search for variants previously associated with testosterone and SHBG levels
			(j) Describe any methods used to address and correct for relatedness among subjects.	Methods: Genotyping and association analysis
Results				
Participants	13*	(a) Report the numbers of individuals at each stage of the study – e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up and analysed.	Report numbers of individuals in whom genotyping was attempted and numbers of individuals in whom genotyping was successful.	Methods: Study cohorts, Genotyping and association analysis, Meta-analysis, Adjusting the GWAS for BMI
		(b) Give reasons for non-participation at each stage.		GWAS IOI BIVII
Descriptive data	14*	(c) Consider use of a flow diagram. (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders. (b) Indicate the number of participants with	Consider giving information by genotype.	Methods: Study cohorts, Genotyping and association analysis, Meta-
		missing data for each variable of interest. (c) Cohort study – Summarize follow-up time, e.g. average and total amount.		analysis, Adjusting the GWAS for BMI
Outcome data	15*	Cohort study – Report numbers of outcome events or summary measures over time.	Report outcomes (phenotypes) for each genotype category over time	Results Figures 1-4, S1, S2 Tables 1, S1
		Case-control study - Report numbers in each exposure category, or summary measures of exposure.	Report numbers in each genotype category	
		Cross-sectional study – Report numbers of outcome events or summary measures.	Report outcomes (phenotypes) for each genotype category	
Main results	16	 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence intervals). Make clear which confounders were adjusted for and why they were included. (b) Report category boundaries when continuous variables were categorized. (c) If relevant, consider translating estimates of relative risk into absolute risk for a 		Results Figures 1-4, S1, S2 Tables 1, S1
		meaningful time period.	(d) Report results of any adjustments for multiple comparisons.	Results: A testosterone- associated variant in intron of PLEKHM3 also associated with PCOS

Other analyses	17	(a) Report other analyses done – e.g. analyses of subgroups and interactions, and sensitivity analyses.		
			(b) If numerous genetic exposures (genetic variants) were examined, summarize results from all analyses undertaken.	A testosterone- associated variant in intron of PLEKHM3 also associated with
				PCOS Table S1
			(c) If detailed results are available elsewhere, state how they can be accessed.	Data availability
Discussion				
Key results	18	Summarize key results with reference to study objectives.		Discussion: Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.		Discussion: Paragraphs 3, 7, 9, 10, 13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.		Discussion: Paragraphs 3, 7, 9, 10, 13
Generalizability	21	Discuss the generalizability (external validity) of the study results.		Discussion, 1, 6, 11, 14
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.		Acknowledgem ents

STROBE: STtrengthening the Reporting of Observational Studies in Epidemiology

^{*}Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.